Skip to main content
Quest Diagnostics

Decreases in Hepatitis C Testing and Treatment During the COVID-19 Pandemic

Decreases in Hepatitis C Testing and Treatment During the COVID-19 Pandemic

Authors: Kaufman HW, Bull-Otterson L, Meyer III WA, Huang X, Doshani M, Thompson WW, Osinubi A, Khan MA, Harris A, Gupta N, Van Handel M, Wester C, Mermin J, Nelson N

Citation: Am J Prev Med. 2021 May10; https://doi.org/10.1016/j.amepre.2021.03.011 Online ahead of print

Specialties: Infectious disease, COVID-19, Internal medicine

Download key summary

Related content

Publication
Assessing vulnerability to COVID 19 in high risk populations: the role of SARS CoV 2 spike targeted serology
Publication
Hepatitis C virus clearance cascade — United States, 2013–2022
Publication
Hepatitis C Virus Testing During Pregnancy Following Universal Screening Recommendations
On-Demand Webinar
Hepatitis C: Implementing the New Guidelines During the Pandemic

Our company

Quest® is the brand name used for services offered by Quest Diagnostics Incorporated and its affiliated companies. Quest Diagnostics Incorporated and certain affiliates are CLIA certified laboratories that provide HIPAA covered services.  Other affiliates operated under the Quest® brand, such as Quest Consumer Inc., do not provide HIPAA covered services. 

 

Quest®, Quest Diagnostics®, any associated logos, and all associated Quest Diagnostics registered or unregistered trademarks are the property of Quest Diagnostics. All third-party marks—® and ™—are the property of their respective owners. © 2024 Quest Diagnostics Incorporated. All rights reserved. Image content features models and is intended for illustrative purposes only.